IPC-klasse
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2007.04.10, US 922759 P
"GENITOURINARY CANCERS", CANCER INVESTIGATION, vol. 25, no. S1, 1 January 2007 (2007-01-01), pages 17-23, XP009158701, ISSN: 0735-7907, DOI: 10.1080/07357900701571783 (B1)
ATKINS M B ET AL: "RANDOMIZED PHASE II STUDY OF MULTIPLE DOSE LEVELS OF CCI-779, A NOVEL MAMMALIAN TARGET OF RAPAMYCIN KINASE INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY RENAL CELL CARCINOMA", JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 5, 1 March 2004 (2004-03-01), pages 909-918, XP008034968, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US ISSN: 0732-183X, DOI: 10.1200/JCO.2004.08.185 (B1)
BURCZYNSKI MICHAEL E ET AL: "Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma", CLINICAL CANCER RESEARCH, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1181-1189, XP002392224, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US ISSN: 1078-0432 (B1)
DUTCHER J. P. ET AL.: "Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)", JOURNAL OF CLINICAL ONCOLOGY & ASCO ANNUAL MEETING PROCEEDINGS, vol. 25, no. 18S, 20 June 2007 (2007-06-20), page 5033, XP002489424, ISSN: 0732-183X (B1)
WO-A-2004/097052 (B1)
M. J. RATAIN: "Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 24, no. 16, 8 May 2006 (2006-05-08), pages 2505-2512, XP055025289, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.03.6723 (B1)
SCHRADER A J ET AL: "Metastatic non-clear cell renal cell carcinoma: current therapeutic options.", BJU INTERNATIONAL, vol. 101, no. 11, June 2008 (2008-06), pages 1343-1345, XP002489425, ISSN: 1464-410X (B1)
WO-A-2004/093854 (B1)
G. HUDES ET AL: "A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)", JOURNAL OF CLINICAL ONCLOLOGY & 2006 ASCO ANNUAL MEETING PROCEEDINGS , vol. 24, no. 18S, LBA4, 20 June 2006 (2006-06-20), XP002674553, Retrieved from the Internet: URL:http://www.asco.org/ascov2/Meetings/Ab stracts?&vmview=abst_detail_view&confID=40 &abstractID=30421 [retrieved on 2012-04-24] (B1)
Statushistorie
| Hovedstatus | Beslutningsdato, detaljstatus |
|---|---|
| Patent opphevet | EP-patent opphevet etter innsigelse i EPO |
| EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
| EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
|
Dato
Type korrespondanse
Journal beskrivelse
|
|---|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Utgående
EP Registreringsbrev (3210)
|
|
Innkommende
Søknadsskjema Patent
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
| Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
|---|---|---|---|---|
| Årsavgift 11. avg. år (EP) | 2018.03.23 | 3500 | MASTER DATA INC | Betalt og godkjent |
| Årsavgift 10. avg. år (EP) | 2017.04.06 | 3200 | Zacco Norway AS | Betalt og godkjent |
| 31612754 expand_more expand_less | 2016.08.15 | 5500 | Zacco Norway AS | Betalt |
|
Valideringsgebyr EP-patent
5500 = 1 X 5500
|